Mometasone Furoate is highly valued in respiratory and ENT formulations for its high topical potency coupled with negligible systemic bioavailability (<1%). For nasal spray applications, our micronized API provides a uniform surface area that allows stable suspension in carboxymethylcellulose or microcrystalline cellulose matrices. This minimizes device clogging and ensures precise, reproducible dosing per actuation.

Classified as a medium-potency (Group II) corticosteroid, the API is widely formulated into 0.1% topical treatments for psoriasis, atopic dermatitis, and corticosteroid-responsive dermatoses. Its balanced lipophilic structure allows it to dissolve efficiently in oleaginous bases and emollient emulsions, ensuring controlled dermal penetration into the stratum corneum without triggering high systemic absorption.

In dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs), crystalline uniformity is paramount. Our API undergoes strict aerodynamic particle size testing to ensure that when blended with lactose carriers, it reaches the lower respiratory tract effectively, maximizing pulmonary anti-inflammatory action while reducing oropharyngeal deposition.